March 7 , 2024
Pharmaceutical executives are navigating through an increasingly complex regulatory landscape due to the Inflation Reduction Act (IRA). It introduced substantial drug cost shifting and now impacts strategic and analytical planning for insurance carriers and drug manufacturers alike. This pivotal legislation brings transparency, and Medicare negotiation to drug pricing, through measures like the 2024 Catastrophic Coverage […]
Amy Bamford Finding, Treating, and Curing Rare Diseases
November 29 , 2021
Picture the following scenario: A patient presents with symptoms including numbness, tremors, and occasional weakness, among others. Genetic testing exists to check for rare cardiovascular diseases and defects, but it is expensive and not currently listed as part of the diagnosis protocol. Because of this, his doctors didn’t order the test. He suffered from these […]
August 18 , 2021
Introduction Do patients benefit from the money that the U.S. Government has spent on the interoperability of clinical systems? The Centers for Medicare and Medicaid Services (CMS) believes that the purpose of the $34 billion dollar Electronic Health Record (EHR) Incentive Programs (aka “Meaningful Use”), is to provide patients with access to their medical records […]
February 11 , 2021
Tune in for a Health Datapalooza Webinar featuring Health and Human Services data leader, hosted by CareSetThe Community Profile Report, a frequently updated national report detailing multiple data streams related to the COVID-19 pandemic, is transforming under the Biden Administration. Learn what this transformation means in relation to transparency of information to the public, and […]